SEC Comment Letter 0000000000-24-012567 to Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc.
Date: Nov. 13, 2024 · CIK: 0001799448 · Accession: 0000000000-24-012567
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283041
Letter
November 13, 2024 Lawrence M. Blatt, Ph.D. President and Chief Executive Officer Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 Re:Aligos Therapeutics, Inc. Registration Statement on Form S-3 Filed November 6, 2024 File No. 333-283041 Dear Lawrence M. Blatt Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mark Roeder, Esq.
Show Raw Text
November 13, 2024
Lawrence M. Blatt, Ph.D.
President and Chief Executive Officer
Aligos Therapeutics, Inc.
One Corporate Dr., 2nd Floor
South San Francisco, CA 94080
Re:Aligos Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 6, 2024
File No. 333-283041
Dear Lawrence M. Blatt Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mark Roeder, Esq.